ScreenerHero

GH Guardant Health, Inc.

NAS · US · Healthcare · Diagnostics & Research · guardanthealth.com
187.22USD+5.30%Mkt Cap: 25.12B $P/E: —

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutati…

Industry Peers

Diagnostics & Research
Screen all
TMO
Thermo Fisher Scientific Inc.
$250.23BUSDP/E 36.4
DHR
Danaher Corporation
$155.51BUSDP/E 39.4
NTRA
Natera, Inc.
$61.35BUSD
LONN
Lonza Group AG
$45.82BUSDP/E 38.1
A
Agilent Technologies, Inc.
$48.29BUSDP/E 33.8
ILMN
Illumina, Inc.
$44.35BUSDP/E 54.8
IQV
IQVIA Holdings Inc.
$43.80BUSDP/E 33.1
WAT
Waters Corporation
$43.21BUSDP/E 111.4
IDXX
IDEXX Laboratories, Inc.
$41.58BUSDP/E 37.0
MTD
Mettler-Toledo International Inc.
$30.89BUSDP/E 34.7
DGX
Quest Diagnostics Incorporated
$25.63BUSDP/E 24.7
LH
Labcorp Holdings Inc.
$25.03BUSDP/E 25.5
RVTY
Revvity, Inc.
$17.56BUSDP/E 75.3
MEDP
Medpace Holdings, Inc.
$17.32BUSDP/E 36.4
CRL
Charles River Laboratories International, Inc.
$14.84BUSD
ERF
Eurofins Scientific SE
$14.05BUSDP/E 26.2
ICLR
ICON Public Limited Company
$12.99BUSDP/E 177.2
BIM
bioMérieux S.A.
$10.02BUSDP/E 20.0
QGEN
Qiagen N.V.
$9.46BUSDP/E 23.2
GRAL
GRAIL, Inc.
$6.88BUSD

Key Statistics

Company
Market Cap25.12B USD
Enterprise Value24.50B USD
Revenue (TTM)1.18B USD
Gross Profit633.01M USD
Net Income (TTM)-416.28M USD
Revenue/Share9.14 USD
Last Price187.22 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees2.5K
CountryUS
SectorHealthcare
IndustryDiagnostics & Research
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-446.70
PEG—
EV/EBITDA-56.91
EV/Revenue20.71
P/S20.17
P/B-106.59
EPS (TTM)-3.50
EPS (Forward)-0.40
52W Range
55.38100% of range187.69
52W High187.69 USD
52W Low55.38 USD
Profitability
Gross Margin64.46%
Oper. Margin-38.25%
EBITDA Margin-36.39%
Profit Margin-42.39%
ROE419.18%
ROA-20.67%
Growth
Revenue Growth44.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-184.76M USD
CapEx (TTM)48.31M USD
FCF Margin2.25%
FCF Yield0.11%
Net Debt643.54M USD
Net Debt/EBITDA-1.49
Balance Sheet
Debt/Equity-17.22
Current Ratio4.03
Quick Ratio3.53
Book Value/Sh-1.67 USD
Cash/Share7.85 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)197.44 USD
Upside (mean)+5.5%
Target Range105.00 USD – 225.00 USD
105.00+5.5% to mean225.00
# Analysts25
Ownership
Shares Out.134.20M
Float129.48M
Insiders3.97%
Institutions100.91%
Short Interest
Short Ratio5.7d
Short % Float8.56%
Short % Out.8.21%
Shares Short11.02M
Short (prev mo.)11.19M
Technical
SMA 50165.33 (+13.2%)
SMA 200123.93 (+51.1%)
Beta1.58
S&P 52W Chg14.58%
Avg Vol (30d)1.94M
Avg Vol (10d)1.86M
Technical Indicators
RSI (14)67.9
MACD5.1457
MACD Signal4.5836
MACD Hist.+0.5621
BB Upper189.01 USD
BB Middle171.99 USD
BB Lower154.96 USD
BB Width19.80%
ATR (14)7.809 USD
Vol Ratio (20d)0.99x